Angiodynamics reports fiscal year 2024 first quarter financial results; reaffirms fiscal year 2024 guidance

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2024, which ended august 31, 2023. “we started fiscal year 2024 with strong performance across both businesses, driven by continued strength from nanoknife.
ANGO Ratings Summary
ANGO Quant Ranking